Jeffrey A Engelman
Overview
Explore the profile of Jeffrey A Engelman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
37527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dimitrieva S, Harrison J, Chang J, Piquet M, Mino-Kenudson M, Gabriel M, et al.
Cancer Res Commun
. 2024 Nov;
4(12):3049-3066.
PMID: 39485038
Pancreatic cancer remains a high unmet medical need. Understanding the interactions between stroma and cancer cells in this disease may unveil new opportunities for therapeutic intervention.
2.
Cotton J, Estrada Diez J, Sagar V, Chen J, Piquet M, Alford J, et al.
Cancer Res
. 2023 Aug;
83(21):3611-3623.
PMID: 37603596
Significance: The evolution and heterogeneity of EGFR inhibitor tolerance are identified in a large number of clones at enhanced cellular and temporal resolution using an expressed barcode technology coupled with...
3.
Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, et al.
Nature
. 2023 Jul;
620(7973):393-401.
PMID: 37407818
Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified, the underlying molecular mechanisms shaping tumour evolution during...
4.
Nair N, Greninger P, Zhang X, Friedman A, Amzallag A, Cortez E, et al.
Nat Commun
. 2023 Jun;
14(1):3830.
PMID: 37380628
Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited efficacy of single agents. The design and testing of combinations are however very challenging. Here we present...
5.
Tiedt R, King F, Stamm C, Niederst M, Delach S, Zumstein-Mecker S, et al.
Cell Rep
. 2023 Mar;
42(4):112297.
PMID: 36961816
Anti-tumor efficacy of targeted therapies is variable across patients and cancer types. Even in patients with initial deep response, tumors are typically not eradicated and eventually relapse. To address these...
6.
Bonazzi S, dHennezel E, Beckwith R, Xu L, Fazal A, Magracheva A, et al.
Cell Chem Biol
. 2023 Mar;
30(3):235-247.e12.
PMID: 36863346
Malignant tumors can evade destruction by the immune system by attracting immune-suppressive regulatory T cells (Treg) cells. The IKZF2 (Helios) transcription factor plays a crucial role in maintaining function and...
7.
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y, Ngankeu A, et al.
Nat Med
. 2022 Oct;
28(11):2436.
PMID: 36195688
No abstract available.
8.
Castel P, Toska E, Engelman J, Scaltriti M
Nat Cancer
. 2022 Feb;
2(6):587-597.
PMID: 35118422
Phosphoinositide-3- kinase (PI3K) signaling regulates cellular proliferation, survival and metabolism, and its aberrant activation is one of the most frequent oncogenic events across human cancers. In the last few decades,...
9.
Hu H, Piotrowska Z, Hare P, Chen H, Mulvey H, Mayfield A, et al.
Cancer Cell
. 2021 Oct;
39(11):1531-1547.e10.
PMID: 34624218
Cancer-associated fibroblasts (CAFs) are highly heterogeneous. With the lack of a comprehensive understanding of CAFs' functional distinctions, it remains unclear how cancer treatments could be personalized based on CAFs in...
10.
Pereira B, Chen C, Goyal L, Walmsley C, Pinto C, Baiev I, et al.
Nat Commun
. 2021 May;
12(1):3199.
PMID: 34045463
In patients with metastatic cancer, spatial heterogeneity of somatic alterations may lead to incomplete assessment of a cancer's mutational profile when analyzing a single tumor biopsy. In this study, we...